Company news
UroGen Pharma Ltd. news in 2021
UroGen Pharma Ltd.'s news releases, calls and decks from 2021, newest first.
First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
December 20, 2021
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
November 14, 2021
UroGen Pharma Announces Upcoming 2021 Conferences
November 10, 2021
UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
November 9, 2021
UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021
October 31, 2021
The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
October 4, 2021
UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting
September 12, 2021
UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 9, 2021
UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
August 3, 2021
UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021
July 27, 2021
UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel
July 27, 2021
UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021
July 13, 2021
UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference
July 6, 2021
UroGen Pharma Announces June 2021 Conference Schedule
May 24, 2021
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments
May 12, 2021
UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
May 5, 2021
UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments
March 17, 2021
UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments
March 17, 2021
UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline
March 14, 2021
UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021
March 10, 2021
UroGen Pharma Announces March 2021 Conference Schedule
February 22, 2021
UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
January 12, 2021
UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021
Calls in 2021
Decks in 2021
- J.P. Morgan 2021 Healthcare Conference
Conference · 29 slides · Jan 11, 2021